Bet bromodomain

Cat.No.	Product Name	Information	Product Use Citations
S1021	Dasatinib	Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.	Cancer Cell, 2025, S1535-6108(25)00070-4 Nat Commun, 2025, 16(1):4069 Cell Rep Med, 2025, 6(9):102310
S8762	dBET6	dBET6 is a highly cell-permeable PROTAC degrader of BET bromodomains with an IC50 of 14 nM for BRD4 binding. dBET6 also induces c-MYC downregulation and apoptosis.	J Nanobiotechnology, 2024, 22(1):692 J Pathol, 2024, 262(1):37-49 Genes Cancer, 2023, 10.18632/genesandcancer.233
S9648	NEO2734 (EP31670)	NEO2734 (EP31670) is a novel, orally active and selective dual inhibitor of p300/CBP and BET bromodomain with IC50 of both <30 nM.	Cell Rep Med, 2024, 5(3):101471 Nat Cancer, 2023, 4(10):1508-1525 PLoS Pathog, 2023, 19(8):e1011598
S6993	(+)-JQ1 carboxylic acid	(+)-JQ1 carboxylic acid ((+)-JQ1-COOH) is a (+)-JQ1 with a carboxylic acid functional group. This compound can be used as a precursor to a PROTAC that targets BET bromodomains after conjugation to a linker and E3 ligase ligand.	J Immunother Cancer, 2023, 11(4)e006070 J Immunother Cancer, 2023, 11(4)e006070
S1021	Dasatinib	Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.	Cancer Cell, 2025, S1535-6108(25)00070-4 Nat Commun, 2025, 16(1):4069 Cell Rep Med, 2025, 6(9):102310
S9648	NEO2734 (EP31670)	NEO2734 (EP31670) is a novel, orally active and selective dual inhibitor of p300/CBP and BET bromodomain with IC50 of both <30 nM.	Cell Rep Med, 2024, 5(3):101471 Nat Cancer, 2023, 4(10):1508-1525 PLoS Pathog, 2023, 19(8):e1011598

BET

Epigenetics